Literature DB >> 21484319

The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study.

Sedigheh Ghandi1, Abbas Aflatoonian, Nasim Tabibnejad, Mohammad Hossein Sojoodi Moghaddam.   

Abstract

PURPOSE: Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome.
METHODS: A total of 80 women were prospectively recruited to receive either metformin (n = 40) or orlistat (n = 40). Weight, BMI, waist, serum LH, total serum testosterone and lipid profile were assessed at baseline and after 3 months. The subjects' ovulatory status was assessed after 3 months.
RESULTS: There was no significant difference in ovulation between the two treatment groups (30% vs 15%). Treatment with either drug showed a significant decline in body weight, BMI (Body Mass Index), and waist circumference, but the degree of decline in both groups was the same. Patients who were treated with orlistat, showed a significant reduction in total testosterone and serum lipid. Women in metformin group showed a significant reduction in serum LH.
CONCLUSIONS: Both metformin and orlistat showed a similar effect on weight loss and ovulation rates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21484319      PMCID: PMC3162050          DOI: 10.1007/s10815-011-9564-2

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  52 in total

1.  Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.

Authors:  E Velázquez; A Acosta; S G Mendoza
Journal:  Obstet Gynecol       Date:  1997-09       Impact factor: 7.661

2.  Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome.

Authors:  A Dunaif; K R Segal; W Futterweit; A Dobrjansky
Journal:  Diabetes       Date:  1989-09       Impact factor: 9.461

3.  Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.

Authors:  D S Kiddy; D Hamilton-Fairley; A Bush; F Short; V Anyaoku; M J Reed; S Franks
Journal:  Clin Endocrinol (Oxf)       Date:  1992-01       Impact factor: 3.478

4.  Modulation of anterior pituitary luteinizing hormone response to gonadotropin-releasing hormone by insulin-like growth factor I in vitro.

Authors:  R Soldani; A Cagnacci; A M Paoletti; S S Yen; G B Melis
Journal:  Fertil Steril       Date:  1995-09       Impact factor: 7.329

5.  Insulin, insulin-like growth factor I (IGF-I) and IGF-II enhance basal and gonadotrophin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro.

Authors:  R Soldani; A Cagnacci; S S Yen
Journal:  Eur J Endocrinol       Date:  1994-12       Impact factor: 6.664

6.  Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome.

Authors:  P Andersen; I Seljeflot; M Abdelnoor; H Arnesen; P O Dale; A Løvik; K Birkeland
Journal:  Metabolism       Date:  1995-05       Impact factor: 8.694

7.  Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.

Authors:  E M Velazquez; S Mendoza; T Hamer; F Sosa; C J Glueck
Journal:  Metabolism       Date:  1994-05       Impact factor: 8.694

8.  Response of sex hormone binding globulin and insulin-like growth factor binding protein-1 to an oral glucose tolerance test in obese women with polycystic ovary syndrome before and after calorie restriction.

Authors:  D Hamilton-Fairley; D Kiddy; V Anyaoku; R Koistinen; M Seppälä; S Franks
Journal:  Clin Endocrinol (Oxf)       Date:  1993-09       Impact factor: 3.478

9.  Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women.

Authors:  A M Clark; W Ledger; C Galletly; L Tomlinson; F Blaney; X Wang; R J Norman
Journal:  Hum Reprod       Date:  1995-10       Impact factor: 6.918

10.  Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss.

Authors:  R Pasquali; D Antenucci; F Casimirri; S Venturoli; R Paradisi; R Fabbri; V Balestra; N Melchionda; L Barbara
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

View more
  6 in total

1.  Effect of orlistat on weight loss, hormonal and metabolic profiles in women with polycystic ovarian syndrome: a randomized double-blind placebo-controlled trial.

Authors:  Ashraf Moini; Mahia Kanani; Ladan Kashani; Reihaneh Hosseini; Ladan Hosseini
Journal:  Endocrine       Date:  2014-10-08       Impact factor: 3.633

Review 2.  Obesity and reproductive function.

Authors:  Emily S Jungheim; Jennifer L Travieso; Kenneth R Carson; Kelle H Moley
Journal:  Obstet Gynecol Clin North Am       Date:  2012-12       Impact factor: 2.844

3.  Orlistat in polycystic ovarian syndrome reduces weight with improvement in lipid profile and pregnancy rates.

Authors:  Pratap Kumar; Shweta Arora
Journal:  J Hum Reprod Sci       Date:  2014 Oct-Dec

Review 4.  Effect of Orlistat Versus Metformin in Various Aspects of Polycystic Ovarian Syndrome: A Systematic Review of Randomized Control Trials.

Authors:  Soumya Ranjan Panda; Madhu Jain; Shuchi Jain; Riden Saxena; Smrutismita Hota
Journal:  J Obstet Gynaecol India       Date:  2018-06-12

5.  The effect of orlistat versus metformin on body composition and insulin resistance in obese premenopausal women: 3-month randomized prospective open-label study.

Authors:  Magdalena Kujawska-Łuczak; Katarzyna Musialik; Monika Szulińska; Ewelina Swora-Cwynar; Angelina Kargulewicz; Małgorzata Grzymisławska; Danuta Pupek-Musialik; Paweł Bogdański
Journal:  Arch Med Sci       Date:  2016-08-29       Impact factor: 3.318

6.  Effects of orlistat on serum androgen levels among iranian obese women with polycystic ovarian syndrome.

Authors:  Saghar Salehpour; Sedighe Hosseini; Leila Nazari; Nasrin Saharkhiz; Shahrzad Zademodarres
Journal:  JBRA Assist Reprod       Date:  2018-09-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.